Tel: + 852 39179825 Fax: +852 39179095

Contact us

research description

My current research interests include mainly two areas: 1) HIV pathogenesis and 2) immunotherapy for curing HIV and cancer.  To understand HIV pathogenesis, I mainly focus on the early events of viral infection in mucosal associated lymph tissues, which may have critical implications for prevention and cure. In recent years, we found that human cytomegalovirus latent infection modulates HIV-1 restriction factors in CD34+ hematopoietic stem cells (Blood Advances 2017).  HIV-induced gut-homing Vd2 T cells upregulate isoformic PD-1 (Δ42PD-1) expression, leading to TLR4-mediated inflammation and acute mucosal damage (Nature Microbiology 2017). Meantime, we found that HIV-infected gut-homing CD4 T cells upregulate CCR7 expression by TGF-b, implicating their lymph node homing and latency established in central memory T cells (Journal of Virology 2018).  Moreover, we recently found that blocking gut-homing CD4 T cells by a4b7-specific antibody is not sufficient to prevent HIV rebound after stopping antiretroviral treatment in humanized mice (AIDS 2019). These studies also establish platforms for evaluation of HIV immunotherapy. To investigate HIV immunotherapeutic cure, we have developed three HKU-patented technologies including PD1-based vaccine (JCI 2013, Cancer Res. 2014), tandem bi-specific antibody (JCI 2018) and anti-Δ42PD1 antibody drug (mAbs 2015). These publications have built a solid foundation for conducting our ongoing study on PD1 vaccine-based combination immunotherapy for a prolonged HIV control by potentiating host immunity.  It should be noted that we are also very interested in applying our knowledge for cancer immunotherapy (Gut 2018, Oncoimmunology 2019).  We, therefore, are fully committed to find solutions to end AIDS and cancer based on scientific discoveries.


DVM. (Sept. 1980 - July 1985), Veterinary Medicine, College of Veterinary Medicine, Northwestern Agricultural University, Shaanxi, P.R. of China

M.Sc. (Sept. 1991 - May 1993), Biology and Molecular Biology, Department of Biology, New Mexico State University, USA (Mentor: Professor Preston A. Marx)

Ph.D. (Jan. 1994 - May 1996), Microbiology, Department of Microbiology, New York University Medical Center, New York University, USA (Mentor: Professor Preston A. Marx)


professional experience

2023 – Present      Director and Tenured Chair Professor; AIDS Institute, Department of Microbiology, School of Clinical Medicine, State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR
2014 – 2023       Director and Tenured Full Professor; AIDS Institute, Department of Microbiology, School of Clinical Medicine, State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR
2007 – 2014      Director and Tenure-track Associate Professor; AIDS Institute, Department of Microbiology, State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR
2002 – 2007     Guest Professor and Ph.D. Advisor, State Key Laboratory of Virology of China, Modern Virology Research Center and AIDS Center, College of Life Sciences, Wuhan University, China
2002 – 2007    Staff Investigator and Assistant Professor, Aaron Diamond AIDS Research Center, The Rockefeller University, New York, USA
1999 – 2002   Research Scientist, Aaron Diamond AIDS Research Center, The Rockefeller University, New York, USA (Mentor: Professor David D. Ho) 
1996 – 1999   Postdoctoral Fellow, Aaron Diamond AIDS Research Center, The Rockefeller University, New York, USA (Mentor: Professor David D. Ho) 


Honours/Awards/other Esteemed Factors

1. Charles H. Revson/Norman and Rosita Winston Fellow 1998

2. US NIH F32 Fellow 1998-2002

3. Clinical Infectious Diseases Award for Outstanding Review 2010

4. JAIDS Outstanding Reviewer Award 2015

5. China New Development Award 2019 (Springer Nature)

6. Faculty Knowledge Exchange Award 2018-19 (HKUMed)

7. Knowledge Exchange Excellence Award 2019 (HKU)

8. Outstanding Researcher Award 2020-21 (HKU)

9. Outstanding Research Student Supervisor Award 2020-21 (HKU)

10. Gold Medal in Inventions Geneva Evaluation 2021

11. Faculty Outstanding Research Output Award 2021 (HKUMed)

12. Most Picked Award - 2021 Chinese Scientists with Cell Press (Cell Press)

13. Bronze Medal in Inventions Geneva Evaluation 2022

14. Faculty Outstanding Research Output Award 2022 (HKUMed)

15. Ranked by Clarivate Analytics as the top 1% worldwide by citations and one of the 38 HKU academics among Highly Cited Researchers 2022

16. Conferment of the title of Chair Professor by the president of The University of Hong Kong 2023


Academic Editor and Editorial Board Member

1.  Immunotherapy Advances, Founding Editorial Board Member, since 2020; Publisher: Oxford University Press, invited by British Society for Immunology

2.  AIDS: Member of Editorial Board, since Jan 2017; Publisher: Lippincott Williams & Wilkins, USA

3.  Journal of Acquired Immune Deficiency Syndromes (JAIDS); Member of Editorial Board, since Jan 2010; Publisher: Lippincott Williams & Wilkins, USA

4.  Journal of Neuroimmune Pharmacology (JNIP); the peer-reviewed journal of the Society on NeuroImmune Pharmacology. Publisher: Springer

5.  Journal of Leukocyte Biology, Guest editor, 2020

6.  Current Opinion in HIV and AIDS, Invited guest editor for the November Issue 2020 on COVID-19, together with the invited Editorial Introduction.

7.  Journal of Medical Primatology, Member of Editorial Board, since 2008; Publisher: Blackwell-Wiley InterScience

8. PLoS ONE, Academic Editor and Member of Editorial Board since 2010; Publisher: Public Library of Science, USA

9. Journal of Antivirals and Antiretrovirals (Editor/Member of Editorial Board, since 2009); Publisher: OMICS Publishing Group

10. Faculty Member of F1000, F1000 Faculty comprises the world’s leading researchers across all of biology and medicine


Organizing or Scientific Committee for International Conferences on HIV/AIDS

1. 2014 Scientific Committee Member, 20th International AIDS Conference, Melbourne, by International AIDS Society

2. 2015 Scientific Advisory Board, Cent Gardes Conference: HIV Vaccines, France

3. 2016 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference

4. 2017 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference

5. 2018 Section chair at The HIV Research for Prevention (HIVR4P) international conference in Madrid

6. 2018 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference

7. 2019 Invited Speaker, Cent Gardes Conference: HIV Vaccines, France

8. 2020 Invited plenary speaker at the Asia-Pacific AIDS & Co-Infections Conference 2020 in Thailand

9. 2020 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference

10. 2020 Section Chair and Plenary Speaker, 5th International Conference & Expo on HIV & AIDS, the HIV-AIDS Summit 2020, Philadelphia, USA

11. 2022 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference

12. IAS 2023: World’s largest scientific conference on HIV (Brisbane) by International AIDS Society, Abstract Selection Panel

13. IAS 2023, Invited Speaker, 2023 HIV Cure & Immunotherapy Forum; Section Chair for Advances in gene delivery and engineering of T and B cells: Implications    for prevention, therapy and cure, Brisbane, Australia


Scientific Committee for National Academic Conference on HIV/AIDS in China

2015-2022  National Academic Conference on HIV/AIDS, vice-chair for the academic committee for this largest annual conference on HIV/AIDS in China


Reviewer for domestic and international grant applications

1. Hong Kong Health and Medical Fund (HMRF)

2. National Natural Science Foundation of China

3. Science, Technology and Innovation Commission of Shenzhen Municipality

4. American Foundation for AIDS Research (amFAR)

5. The Bill & Melinda Gates Foundation

6. Netherlands Organization for Scientific Research

7. British St Stephen’s AIDS Trust


Professional Services at HKU and Local Community

1.  Director, AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong; July 2007 – present
2.  Council member, Hong Kong Society for Immunology; Term: 2015 – present
3.  Chairman, Hong Kong Society for Immunology; Term: 2018 – 2020
4.  Member, Faculty BBMS Organizing Committee and Curriculum Committee; Term: 2015 – 2020
5.  Member, Faculty High Degree Committee; Term: 2016 – 2019
6.  Member, Advisory Council on AIDS, Department of Health, HKSAR; Term: 2008 – 2014
7.  Board Director, Friends of Hope Education Fund, Hong Kong SAR; Term: 2008 – 2019; Initiated the AIDS orphan educational program, honorary board member
8.  Board Director, AIDS Concern, Hong Kong SAR; Term: 2013 – 2016
9.  Board Director, Hong Kong AIDS Foundation, Hong Kong SAR; Term: 2019 – present; to promote HIV education and preventions programs


The American Society and Association Membership

1. The American Society for Microbiology

2. The American Association of Immunologists

3. American Society on NeuroImmune Pharmacology

4. International AIDS Society


Reviewer for peer-reviewed international journals

AIDS, JAIDS, Immunity, Science Translational Medicine, Journal of Virology, Journal of Clinical Investigation, Journal of Experimental Medicine, Emerging Microbes & Infections, Virology, Clinical Infectious Diseases, Journal of Infectious Diseases, Clinical Chemistry, Journal of Virological Methods, PLoS One, Journal of Immunology, Applied Microbiology and Biotechnology, Viruses, etc.



Fellowship, Awards and Grants in the USA

1998-1999   Fellowship award from the Charles H. Revson/Norman and Rosita Winston Foundation, The Rockefeller University. Role: Principal Investigator
1998-2002    Grant funded by National Institutes of Health (NIH/NIAID, 1F32AI 10256), Characterization of a CCR2-tropic recombinant simian immunodeficiency virus; Role: Principal Investigator
2000-2001    Grant funded by the American Foundation for AIDS Research (amFAR, 02663-27-RGM); Development of a Novel SHIV/Macaque Model for Microbicide Testing, US$120,000; Role: Principal Investigator
2005-2009    Grant from National Institutes of Health, USA; (NIH RO1 HL080211-01); US$2.4 million; A Novel Model for the Study of Lung Pathogenesis of SARS; Role: Principal Investigator


External Grants Received from the USA for Research at HKU (HK$7.3 million to my group at HKU)


2007-2009    Grant from National Institutes of Health, USA; (NIH 5 R01 HL080211-03); US$2.4 million; A Novel Model for the Study of Lung Pathogenesis of SARS; Role: Principal Investigator; (US$292,450 to my HKU Lab)
2007-2011   Grant from National Institutes of Health, USA; (NIH 3 R01 DA020419-02S1); Cannabinoid effects on HIV/AIDS; US$320,000, Role: Co-Principal Investigator
2008-2009   Grant BMGF 52117, Bill & Melinda Gates Foundation; Preventing HIV-1 infection using a novel vaccine immunogen; US$100,000; Role: Principal Investigator
2017-2021    Grant from Bill & Melinda Gates Foundation for the National Institutes of Health (AR170035), USA; Structure-Based Vaccine Design against HIV-1, US$220,000; Role: Co-Principal Investigator


External Grant Received from the UK for Research at HKU (HK$3.18 million to my group at HKU)


2020-2022    Grant from Wellcome Trust (the Funder) for project entitled "A comprehensive study of immunopathogenesis of SARS-CoV-2 infection", £315,689.63 to my group at HKU, Role: Co-Principal Investigator


External Grant Received from the Coalition for Epidemic Preparedness Innovations (CEPI) for COVID-19 Vaccine Research at HKU (HK$48.36 million)


2020-2020  Phase I US$600,000, Role: Co-Principal Investigator

2020-2022  Phase II US$5,600,000, Role: Co-Principal Investigator


External Awards and Grants Received from Australia for Research at HKU (HK$590300 to my group)


2020-2022    Grant from Australian MRFF 2020 COVID-19 Vaccine Candidate Grant Opportunity for project entitled “A safe, effective, and rapidly tuneable SARS-CoV-2 vaccine”, A$100K. Role: Co-Investigator


External Awards and Grants Received in Hong Kong as PI (HK$110 million to my group)


2008-2009   Grant RGC-GRF 762208M, HKSAR; Mucosal vaccine against HIV-1 infection; HK$517,190; Role: Principal Investigator
2008-2009    Understanding the Ongoing HIV Epidemic in Yunnan China; Supported by China AIDS Initiative (Hong Kong Committee); HK$196,000; Role: Principal Investigator
2009-2012   Grant RGC-GRF 762209M, HKSAR; Role of the PD-1/PD-L pathway in AIDS vaccine design; HK$944,700; Role: Principal Investigator
2010-2012   Grant RFCID 09080772, HKSAR; Characterization of novel anti-HIV/TB natural product analogues, HK$800,000; Role: Principal Investigator
2011-2013    AIDS Trust Fund (ATF) MSS 183 R, HKSAR; Establishment of a rapid, high-throughput, cost-effective HIV-1 drug resistance testing system; HK$1,573,000; Role: Principal Investigator
2011-2013    Pneumoconiosis Compensation Fund Board (PCFB), HKSAR; A Novel Vaccine for Mesothelioma Immunotherapy and Prevention; HK$1,718,000; Role: Principal Investigator
2011-2013   Grant RFCID 11101022, HKSAR, A Novel Vaccine for Tuberculosis Prevention; HK$994,560; Role: Principal Investigator
2012-2014   Grant RGC-GRF 762811M, HKSAR; A Promising Mucosal Prime and Intramuscular Boost AIDS Vaccine Regimen; HK$950,000; Role: Principal Investigator
2012-2015   Grant RGC-NSFC N_HKU 709/11, HKSAR; HIV prevention using gene-encoded neutralizing antibodies; HK$892,290; Role: Principal Investigator
2013-2015   Grant Information Technology Fund (ITF) GHX/013/11SZ, HK$682,642. Phenotypic Assay for HIV drug resistance; Role: Principal Investigator
2013-2016    Grant RGC-GRF 762712, HKSAR; Mechanism of soluble PD-1 based vaccine in amplifying antiviral CD8+ T-cell immunity; HK$1,248,250; Role: Principal Investigator
2014-2016   Grant ITF ITS/194/13, HKSAR; A New Therapeutic Vaccine for HIV/AIDS; HK$1,391,400; Role: Principal Investigator
2014-2017   Grant RGC-CRF HKU5/CRF/13G, HKSAR; Mechanism of potentiating HIV antigen-specific CD8+ T cells; HK$7,984,380; Role: Project Coordinator
2014-2017    Grant ATF MSS 227R, HKSAR; The level of GFAP as a specific biomarker of neuroAIDS among Chinese patients; HK$1,904,800; Role: Principal Investigator
2015-2016    Grant PCFB, HKSAR; Induction of Mesothelioma-Specific CD8+ T cells Response for Immunotherapy and Prevention; HK$1,361,090; Role: Principal Investigator
2015-2019    Grant RGC-ANR A-HKU709/14, HKSAR; A novel DNA-based vaccination strategy to mimic Gag­ specific responses found in HIV Elite Controllers; HK$2,550,110; Role: Principal Investigator
2015-2017   Grant RGC-GRF 17103514, HKSAR; Role of a newly identified PD-1 isoform in modulating immune responses; HK$1,144,050; Role: Principal Investigator
2015-2017   Grant HMRF 14130582, HKSAR; Role of Delta 42PD-1 in HIV Infection; HK$999,980; Role: Principal Investigator
2016-2018    Grant RGC-GRF 17122915, HKSAR; Role of PD-1 Based Vaccine-Elicited CD8+ T Lymphocytes in Modulating MDSC-associated Immunosuppression; HK$977,450; Role: Principal Investigator
2017-2018   Grant PCFB, HKSAR; Induction of Mesothelioma-Specific CD8+ T cells Response for Immunotherapy and Prevention; HK$1,499,980; Role: Principal Investigator
2018-2019   Grant ITF ITS/170/17, HKSAR; A Novel Therapeutic AAV-vectored Bi-Specific Neutralizing Antibody against HIV/AIDS; HK$1,399,550; Role: Principal Investigator
2018-2019   Grant ITF UIM/314, HKSAR; A novel PD1-based vaccine for HIV/AIDS Immunotherapy; HK$11,998,000; Role: Principal Investigator
2018-2019    Grant PCFB, HKSAR; Enhancing immunotherapeutic efficacy of mesothelioma by overcoming MDSC-mediated immunosuppression; HK$1,414,330; Role: Principal Investigator
2018-2021   Industry Contract Research, A Humanized anti-d42PD1 antibody against human inflammatory disease and cancer, HK$4,000,000; Role: Principal Investigator
2019-2021   Grant RGC-GRF 17115818, HKSAR; Role of Δ42PD-1 in Human Dendritic Cells during HIV-1 Infection; HK$971,900; Role: Principal Investigator
2019-2021    Grant HMRF 18170762, HKSAR; HIV-1 mucosal prevention and immunotherapy by engineered tandem bi-specific IgA; HK$1,499,940; Role: Principal Investigator
2019-2023   Grant RGC-TRS T11-706/18-N, HKSAR; Potentiating Host Immunity for HIV-1 Functional Cure; HK$47.128 million; Role: Project Co-ordinator
2020-2022    Grant RGC-GRF 17104919, HKSAR; Mechanism of a Δ42PD-1-specific humanized antibody huCH101 in treating HIV/AIDS; HK$1,115,990; Role: Principal Investigator
2021-2023    Grant RGC-GRF 17121420, HKSAR; Combined BiIA-SG and anti-TRABD2A antibody for HIV-1 Functional Cure; Role: Principal Investigator
2021-2024   Grant RGC-CRF C7156-20G, HKSAR; Mechanism of Immune Control against COVID-19; HK$8,979,578; Role: Project Coordinator
2022-2025    Grant RGC-GRF 17117422, HKSAR; Mechanism of vaccine-induced mucosal immune responses against SARS-CoV-2 infection; HK$1,179,038; Role: Principal Investigator
2023-2026    Grant RGC-GRF 1711923, HKSAR; Role of HIV-1-specific antibodies cloned from Δ42PD-1 positive memory B cells; Role: Principal Investigator


External Awards and Grants Received in Hong Kong as Co-PI (HK$69 million to my group at HKU)


2015-2018     Grant RGC-CRF C7038-14G, HKSAR; Investigation of effects and molecular mechanisms of FGFR2-positive cancer-associate fibroblasts on tumor microenvironment in esophageal squamous cell carcinoma; HK$800,000; Role: Co-Principal Investigator
2017-2020   Grant from Sanming Project (AR160087); Study on AIDS Vaccine and Immunotherapy; HK$2,230,000; Role: Project Leader
2019-2022    Grant RGC-CRF C4045-18W, HKSAR; Deciphering Enhancer Regulation of Tumor Immune Evasion to Develop New Combination Immunotherapies; HK$1,200,000; Role: Co-Principal Investigator
2020-2022    HMRF Commissioned Research (COVID190123); “Clinical study of flu-based and PD1-based vaccines for the SARS-CoV-2”; HK$10 million (from the total of HK$20,337,934; Role: Co-Principal investigator
2020-2025     Grant RGC-TRS T12-703/19-R, HKSAR; Fighting Disease Recurrence and Promoting Tissue Repair after Liver Transplantation: Translating Basic Discoveries to Clinical Excellence; HK$6,000,000; Role: Co-Principal Investigator
2020-2025    InnoHK “Centre for Virology, Vaccinology and Therapeutics”, HKSAR; HK$47 million; Role: Project Co-Principal Investigator (from the total budget of about HK$400 million).
2021-2024    Grant RGC-CRF C1134-20G, HKSAR; A novel vaccination strategy: using a microrobot platform for DNA vaccine delivery and antigen presentation; HK$1,000,000; Role: Co-Principal Investigator
2022-2026    Grant RGC-TRS T11-709/21-N, HKSAR; Ecology, Molecular Virology and Pathogenesis of SARS-CoV-2: From Bedside to Bench and Back; HK$1,000,000; Role: Co-Principal Investigator


External Awards and Grants Received for Research in Mainland China   (RMB¥24.9 million)


2006-2010   Chinese 973 Research Program on HIV/AIDS; RMB¥600,000; Role: Project 8 Leader
2008-2010   Grant from the China Ministry of Health; Novel AIDS mucosal vaccine (2008ZX10001-011); RMB ¥2,800,000; Role: Project Leader
2008-2010   Grant from the China Ministry of Health; (2008ZX10001-015); Microbicide against HIV; RMB ¥1,500,000; Role: Project Leader
2012-2015    Grant from the China Ministry of Health; Novel AIDS mucosal vaccine (China’s Major Project of the National Science & Technology 2012ZX10001-009); RMB ¥6,100,000; Role: Project 1 Leader
2013-2016     Grant from the China Ministry of Health; Novel Anti-HIV Antibody for Prevention (China’s Major Project of the National Science & Technology 2017ZX10201101-004); RMB ¥3,000,000; Role: Project 4 Leader
2020-2022    Grant from the Shenzhen Government at HKU SZH; PD1-based COVID-19 vaccine (ICCOV); JSGG20200225151410198; RMB ¥8,000,000; Role: Principal Investigator
2020-2022    Sub-grant from the Ministry of Science and Technology at HKU SZH; Mechanism of antibody-enhanced SARS-CoV-2 infection; 2020YFC0860600; RMB ¥500,000; Role: Co-Investigator
2022-2023    Grant from the Shenzhen Government at HKU SZH; Development portable Raman instrument for COVID disease detection; JSGG220220606141800002; RMB ¥2,400,000; Role: Co-Investigator


Selected Peer-reviewed International Publications:   (*Corresponding author)


Chen Z, Telfer P, Reed P, Zhang L, Getti A, Ho DD and Marx PA. Isolation and characterization of the first simian immunodeficiency virus from a feral sooty mangabey (Cercocebus atys) in West Africa. Journal of Medical Primatology. 24:108-115, 1995.

Chen Z, Telfer P, Gettie A, Reed P, Zhang L, Ho DD and Marx PA. 1996. Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop. Journal of Virology. 70:3617-3627, 1996.

Chen Z, Luckay A, Sodora DL, Telfer P, Reed P, Gettie A, Kanu JM, Sadek RF, Yee J, Ho DD, Zhang L and Marx PA. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus infected sooty mangabeys. Journal of Virology. 71:3953-3960, 1997.

Chen Z, Zhou P, Ho DD, Landau NR and Marx PA. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. Journal of Virology. 71:2705-2714, 1997.

Chen Z, Gettie A, Ho DD and Marx PA. Primary SIVsm isolates use the CCR5 co-receptor from sooty mangabeys naturally infected in West Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2 and SIVmac. Virology. 246:113-124, 1998.

Marx PA and Chen Z. The function of simian chemokine receptors in the replication of SIV. Seminars in Immunology. (Invited review article) 10:215-223, 1998.

Chen Z, Kwon D, Jin Z , Monard S, Telfer P, Jones MS, Aguilar R, Ho DD and Marx PA. Natural infection of a homozygous deleted CCR5 red-capped mangabey with a CCR2b-tropic simian immunodeficiency virus. Journal of Experimental Medicine. Dec 7;188(11):2057-65, 1998.

Chen Z, Huang Y, Zhao X, Skulsky E, Lin D, Ip J, Gettie A and Ho DD. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina). Journal of Virology. 74:6501-10, 2000.

Chen Z, Zhao X, Huang Y, Huang YL, Gettie A, Ba L, Blanchard J and Ho DD. CD4+ Lymphocytopenia in Acute Infection of Asian Macaques by a Vaginally Transmissible Subtype-C, CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV). Journal of Acquired Immune Deficiency Syndromes. 30:133-145, 2002.

Lue J, Hsu M, Yang D, Marx P, Chen Z*, and Cheng-Mayer C. Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. Journal of Virology. Oct;76(20):10299-306, 2002.

Pohlmann S, Zhang J, Baribaud F, Chen Z*, Leslie GJ, Lin G, Granelli-Piperno A, Doms RW, Rice CM, McKeating JA. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. Journal of Virology. Apr;77(7):4070-80, 2003.

Zhuang K, Gui X, Su B, Tien P, Chen Z*, Gui XZhang L. High prevalence of HIV infection among women and their children in Henan Province, China. Journal of Acquired Immune Deficiency Syndromes. 33(5):649-50. 2003.

Su B, Liu L, Wang F, Gui X, Zhao M, Tien P, Zhang L and Chen Z*. HIV-1 subtype B’ dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. AIDS. 21;17(17):2515-20. 2003.

Wu Z, Chen Z, Phillips DM. Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ Cells: implications for mechanisms of sexual transmission. The Journal of Infectious Diseases.. 188(10):1473-82. 2003.

Kao RY, Tsui WH, Lee TS, Tanner JA, Watt RM, Huang JD, Hu L, Chen G, Chen Z, Zhang L, He T, Chan KH, Tse H, To AP, Ng LW, Wong BC, Tsoi HW, Yang D, Ho DD, Yuen KY. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chemistry & Biology.. 2004 Sep;11(9):1293-9.

Zhang L, Chen Z, Cao Y, Yu J, Li G, Yu W, Yin N, Mei S, Li L, Balfe P, He T, Ba L, Zhang F, Lin HH, Yuen MF, Lai CL, Ho DD. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in China. Journal of Virology. 78(24):13591-9. 2004. (Shared the first author)

Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. Journal of Virology. 79(5):2678-88. 2005.

Fang Q, Yang L, Zhu W, Liu L, Wang H, Yu W, Xiao G, Tien P, Zhang L, Chen Z*. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology. 10;335(2):242-51. 2005.

Yi CE, Ba L, Zhang L, Ho DD, Chen Z*. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. Journal of Virology. Sep;79(18):11638-46. 2005.

Woo PC, Lau SK, Tsoi HW, Chen Z*, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine.. Oct 10;23(42):4959-4968. 2005.

Q, Shi Y, Yan W, Chang G, Zhang L, Ho DD, Chen Z*. Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Medicine. 2006 Nov;3(11):e443.

Liu L, Fang Q, Deng F, Wang H, Yi C, Ba L, Yu W, Lin RD, Li T, Hu ZH, Ho DD, Zhang L, Chen Z*. Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus. Journal of Virology. 2007. May;81(9):4694-700.

Ba L, Yi CE, Zhang L, Ho DD, Chen Z*. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. Applied Microbiology and Biotechnology. 2007 Oct;76(5):1131-6.

Chen Z, Huang Y, Zhao X, Ba L, Zhang W and Ho DD. Design, Construction, and Characterization of a Multigenic Modified Vaccinia Ankara Candidate Vaccine against Human Immunodeficiency Virus Type 1 Subtype C/B’. Journal of Acquired Immune Deficiency Syndromes. 2008 Apr 1;47(4):412-21.

Huang Y, Chen Z, Zhang W, Song Y, Zhao X, Gardiner DF and Ho DD. Design, Construction, and Characterization of a Dual-Promoter Multigenic DNA Vaccine Directed against an HIV-1 Subtype C/B’ Recombinant. Journal of Acquired Immune Deficiency Syndromes. 2008 Apr 1;47(4):403-11.

Chen YX, Liu L, Wei Q, Zhu H, Jiang H, Tu XM, Qin C and Chen Z*. Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques. Virology. 2008 Nov 10;381(1):89-97.

Lu L, Jia M, Ma Y, Yang L, Chen Z, Ho DD, Jiang Y, Zhang L. The Changing Face of HIV in China. Nature. Oct 2. 455:609-11, 2008.

Luo M, Liu H, Zhuang K, Liu L, Su B, Yang R, Tien P, Zhang L, Gui X and Chen Z*. Prevalence of drug resistant HIV-1 in rural areas of Hubei province in the People’s Republic of China. Journal of Acquired Immune Deficiency Syndromes. Jan 1; 50(1): 1-8. 2009.

Huang XX, Lu B, Fang Q, Yu W, Liu L, Zhuang K, Shen TT, Wang HB, Tian P, Zhang L, and Chen Z*. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS ONE. 2009;4(1):e4180.

Cheng S, LI J, Lin B, Lee D, Liu L, Chen Z, Lau A. HIV-1 trans-activator protein induction of suppressor of cytokine signaling-2 contributes to dysregulation of IFN signaling. Blood. 2009 May 21;113(21):5192-201.

Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa, Huang Y, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Dally L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD. Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-based Clade C/B’ HIV-1 Candidate Vaccine. PLoS ONE. 2010 Jan; 5(1):e8816.

Xue H, Lu XF, Zheng PR, Liu L, Han CY, Hu JP, Liu ZJ, Ma T, Li Y, Wang L, Chen Z* and Liu G*. Highly suppressing wild-type HIV-1 and Y181C Mutant HIV-1 Strains by 10-Chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile. Journal of Medicinal Chemistry. 53(3), pp1397-1401. 2010.

Yu W, Fang Q, Zhu W, Wang H, Tien P, Zhang L, and Chen Z*. One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT (ZCI) protects animals against pathogenic viral challenge. Vaccine. 2010 Feb 25;28(9):2088-96.

Wang H, Zhuang K, Liu L, Tang Z, Tang J, Tien P, Zhang L, and Chen Z*. Acute infection of Chinese macaques by a CCR5-tropic SHIV carrying a primary HIV-1 subtype B’ envelope. Journal of Acquired Immune Deficiency Syndromes. Mar 1:53(3):285-291. 2010.

Liu H, Yu W, Zhu W, Wang H, and Chen Z*. The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice. Journal of Medical Virology. 2010 May;82(5):727-34.

Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, Jiang H, Zhou J, Lam P, Zhang L, Lackner A, Qin C, Chen Z*. Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tract of Rhesus Macaques. Journal of Virology. 2011. 85(8b):4025-4030.

Lu B, Yu W, Huang XX, Wang H, Liu L, and Chen Z*. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine, vaccinia Tiantan strain. Journal of Biomedicine and Biotechnology. 2011;2011:970424.

Lu X, Liu L, Zhang X, Lau TC, Tsui SK, Kang Y, Zheng P, Zheng B, Liu G, Chen Z*. F18, a novel small molecule NNRTI, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. Antimicrob Agents Chemother. 2012 Jan;56(1):341-51.

Yao X, Wang H, Yan P, Lu Y, Lin H, Chen L, Ng J, Lau E, Li L, Wu J, Chen Z*. Rising epidemic of HIV-1 infections among general populations in Fujian, China. Journal of Acquired Immune Deficiency Syndromes. 2012 Jul; 60(3): 328-35.

Kang Y, Wu Z, Lau TC, Lu X, Liu L, Cheung AK, Tan Z, Ng J, Liang J, Wang H, Li S, Zheng B, Li B, Chen L, Chen Z*. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant. The Journal of Biological Chemistry. 2012 May; 287(20):16499-509.

Kang Y, Guo J and Chen Z*. Closing the door to human immunodeficiency virus. Protein & Cell. 2013 Feb; 4(2):86-102 (Invited Review Article)

Zhou J, Cheung AKL, Tan Z, Wang H, Kang Y, Du Y, Lu X, Liu L, Yuen KY and Chen Z*. PD1-based DNA vaccine amplifies HIV-1 CD8+ T cells in mice. Journal of Clinical Investigation. 2013 Jul; 123(6):2629–2642.

Sun C, Chen Z*, Tang X, Zhang Y, Feng L, Du Y, Xiao L, Liu L, Chen L, Zhang L. Mucosal Prime with a Replicating Vaccinia-based Vaccine Elicits Protective Immunity against SIV Challenge in Rhesus Monkeys. Journal of Virology. 2013 May; 87(10):5669-77. (Shared first author and corresponding author)

Zhou J, Cheung AKL, Liu H, Tan Z, Tang X, Kang Y, Du Y, Wang H, Liu L, and Chen Z*. Potentiating functional antigen-specific CD8+ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine. Molecular Therapy. 2013 Jul; 21(7):1445-55.

Peng Q, Wang H, Wang H, Li X, Lu X, Zhou B, and Chen Z*. Imbalances of gut-homing CD4+ T cell subsets in HIV-1 infected Chinese patients. Journal of Acquired Immune Deficiency Syndromes. 2013 Sep; 64(1):25-31.

Xiao H, Liu L, Zhu Q, Tan Z, Yu W, Tang X, Zhan D, Du Y, Wang H, Liu D, Li Z, Yuen KY, Ho DD, Gao GF, Chen Z*. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PLoS One. 2013 Dec 17;8(12):e83274.

Tan Z, Zhou J, Cheung AK, Yu Z, Cheung KW, Liang J, Wang H, Lee BK, Man K, Liu L, Yuen KY, Chen Z*. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. Cancer Research. 2014 Aug; 74:6010-21.

Guo J, Zuo T, Cheng L, Wu X, Tang J, Sun C, Feng L, Chen L, Zhang L, Chen Z*. Simian immunodeficiency virus infection evades vaccine-elicited antibody responses to V2 region. Journal of Acquired Immune Deficiency Syndromes. 2015 Apr; 68(5):502-10.

Cheng L, Tang X, Liu L, Peng J, Nishiura K, Cheung AK, Guo J, Wu X, Tang HY, An M, Zhou J, Cheung KW, Wang H, Guan X, Wu Z, Chen Z*. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. MAbs 2015 July; 7(3): 620-9.

Zhe Y, Tan Z, Lee BK, Tang J, Wu X, Cheung KW, Lo NTL, Man K, Liu L, Chen Z*. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells. Oncotarget. 2015 Oct; 6(32): 32426-38.

Liu L, Wei Q, Nishiura K, Peng J, Wang H, Midkiff C, Alvarez X, Qin C, Lackner A and Chen Z*. Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunology. 2016 Jul; 9(4):1089-101.

Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen É, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine. 2016 Aug;22(8):839-50.

Li MD, Hser YI, Chen Z, Chang L. Promoting Global Health - Prevention and Treatment of Substance Abuse and HIV in Asia. Journal of Neuroimmune Pharmacology. 2016 Sep;11(3):379-82.

Wu X, Liu L, Cheung KW, Wang H, Lu X, Cheung AK, Liu W, Huang X, Li Y, Chen ZW, Chen SM, Zhang T, Wu H, Chen Z*. Brain Invasion by CD4(+) T Cells Infected with a Transmitted/Founder HIV-1BJZS7 During Acute Stage in Humanized Mice. Journal of Neuroimmune Pharmacology. 2016 Sep; 11(3):572-83.

Wei Q, Liu L, Cong Z, Wu X, Wang H, Qin C, Molina P, Chen Z*. Chronic Δ(9)-Tetrahydrocannabinol Administration Reduces IgE(+)B Cells but Unlikely Enhances Pathogenic SIVmac251 Infection in Male Rhesus Macaques of Chinese Origin. Journal of Neuroimmune Pharmacology. 2016 Sep;11(3):584-591.

Cheung A.K., Huang Y., Kwok H.Y., Chen M., Chen Z*. Latent human cytomegalovirus enhances HIV-1 infection in CD34+ progenitor cells. Blood Advances. 2017 Jan; 1(5):306-318.

Cheung AK, Kwok HY, Huang Y, Chen M, Mo Y, Wu X, Lam KS, Kong HK, Lau TCK, Zhou J, Li J, Cheng L, Lee BK, Peng Q, Lu X, An M, Wang H, Shang H, Zhou B, Wu H, Xu A, Yuen KY, Chen Z*. Gut-homing Δ42PD1+Vδ2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1 infection. Nature Microbiology. 2017 Oct;2(10):1389-1402.

Tang X, Guo J, Cheng L, Sun C, Liu L, Zuo T, Wang H, Chen L, Zhang L, Chen Z*. Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses. Vaccine. 2017 May 2;35(19):2582-2591.

Wu X, Guo J, Niu M, An M, Liu L, Wang H, Jin X, Zhang Q, Lam KS, Wu T, Wang H, Wang Q, Du Y, Li J, Cheng L, Tang HY, Shang H, Zhang L, Zhou P, Chen Z*. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. Journal of Clinical Investigation. 2018 Apr 23. pii: 96764.

Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2018 May;67(5):931-944.

Liu W, Wong YC, Chen SMY, Tang J, Wang H, Cheung AKL, Chen Z*. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses. Vaccine. 2018 Jul 25;36(31):4621-4632.

Cheung KW, Wu T, Ho SF, Wong YC, Liu L, Wang H, Chen Z*. α4β7 CD4 effector/effector memory T cells differentiate into productively and latently infected central memory T cells by transforming growth factor β1 during HIV-1 infection. Journal of Virology 2018 Mar 28;92(8). pii: e01510-17.

Ling L, Tang X, Huang X, Li J, Wang H, Chen Z*. AAV-Vectored Fms-Related Tyrosine Kinase 3 Ligand Inhibits CD34+ Progenitor Cell Engraftment in Humanized Mice. Journal of Neuroimmune Pharmacology. 2018 Dec;13(4):541-550.

Chen Z. Monkey Models and HIV Vaccine Research. Adv Exp Med Biol. 2018;1075:97-124. doi: 10.1007/978-981-13-0484-2_5.PMID: 30030791

Tang J, Cai Y, Liang J, Tan Z, Tang X, Zhang C, Cheng L, Zhou J, Wang H, Yam WC, Chen X, Wang H, Chen Z*. In vivo electroporation of a codon-optimized BERopt DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge. Tuberculosis (Edinb). 2018 Dec;113:65-75.

Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok HY, Tang HY, Nishiura K, Peng J, Tan Z, Wu T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen Z*. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. Journal of Clinical Investigation Insight. 2019 Feb 21;4(4). pii: 123158.

Ling L, Wu T, To KKW, Cheung KW, Lui KO, Niu M, Lam KS, Wang CC, Li J, Wang H, Yuen KY, Chen Z*. Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after cART interruption in humanized mice. AIDS. 2019 Jan 14.

Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F, Cheung OK, Sun H, Zeng X, Tang W, Mok MT, Wong J, Yeung PC, Lai PBS, Chen Z, Jin H, Chen J, Chan SL, To KF, Sung JJ, Chen M, Cheng AS. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut. 2019 May 10. pii: gutjnl-2018-317257. doi: 10.1136/gutjnl-2018-317257

Wang P, Zheng M, Lau SY, Chen P, Mok BW, Liu S, Liu H, Huang X, Cremin CJ, Song W, Chen Y, Wong YC, Huang H, To KK, Chen Z, Xia N, Yuen KY, Chen H. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. mBio. 2019 Sep 17;10(5):e02180-19

Tang X, Zhang S, Peng Q, Ling L, Shi H, Liu Y, Cheng L, Xu L, Cheng L, Chakrabarti LA, Chen Z, Wang H, Zhang Z. Sustained IFN-I stimulation impairs MAIT cell responses to bacteria by inducing IL-10 during chronic HIV-1 infection. Science Advances. 2020 Feb 19;6(8):eaaz0374. doi: 10.1126/sciadv.aaz0374. eCollection 2020 Feb.PMID: 32128419.

Tan Z, Chiu MS, Yan CW, Wong YC, Huang H, Man K, Chen Z*. Anti-mesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination. Molecular Therapy Oncolytics. 2020;16:302-317.

Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, Chan WM, Fan Z, Tsoi HW, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai JP, Kok KH, Chu H, Chan KH, Sridhar S, Chen Z, Chen H, To KK, Yuen KY. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clinical Infectious Diseases. 2020 Mar 26:ciaa325.

To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infectious Diseases. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1.

Liu L, To KK, Chan KH, Wong YC, Zhou R, Kwan KY, Fong CH, Chen LL, Choi CY, Lu L, Tsang OT, Leung WS, To WK, Hung IF, Yuen KY, Chen Z*. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerging Microbes & Infections. 2020 Jul;9(1):1664-1670. doi: 10.1080/22221751.2020.1791738.

Zhou R, To KK, Wong YC, Liu L, Zhou B, Li X, Huang H, Mo Y, Luk TY, Lau TT, Yeung P, Chan WM, Wu AK, Lung KC, Tsang OT, Leung WS, Hung IF, Yuen KY,  Chen Z*. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020 Oct 13;53(4):864-877.e5. doi: 10.1016/j.immuni.2020.07.026

To KK, Hung IF, Chan KH, Yuan S, To WK, Tsang DN, Cheng VC, Chen Z, Kok KH, Yuen KY. Serum antibody profile of a patient with COVID-19 reinfection. Clinical Infectious Diseases. 2020 Sep 23:ciaa1368.

Yuan S, Chu H, Huang J, Zhao X, Ye ZW, Lai PM, Wen L, Cai JP, Mo Y, Cao J, Liang R, Poon VK, Sze KH, Zhou J, To KK, Chen Z, Chen H, Jin DY, Chan JF, Yuen KY. Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target. Science Advances. 2020 Aug 28;6(35):eaba7910

Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020 Aug;584(7821):450-456.

Liu L, Lin Q, Peng J, Fang J, Tan Z, Tang H, Kwan K, Nishiura K, Liang J, Kwok H, Du Z, Sun J, Liu K, Yuen KY, Wang H, Chen Z*. Persistent lentivirus infection induces early myeloid suppressor cells expansion to subvert protective memory CD8 T cell response. EBioMedicine. 2020 Sep 23; 60:103008.

Chen Z. Editorial: The battle for survival between severe acute respiratory syndrome coronavirus 2 and human beings. Current Opinion HIV AIDS. 2020 Nov;15(6):325-327.

Zhou D, Chan JF, Zhou B, Zhou R, Li S, Shan S, Liu L, Zhang AJ, Chen SJ, Chan CC, Xu H, Poon VK, Yuan S, Li C, Chik KK, Chan CC, Cao J, Chan CY, Kwan KY, Du Z, Lau TT, Zhang Q, Zhou J, To KK, Zhang L, Ho DD, Yuen KY, Chen Z*. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host Microbe. 2021 Feb 25:S1931-3128(21)00098-6. doi: 10.1016/j.chom.2021.02.019.

Yang W, Feng Y, Zhou J, Cheung OK, Cao J, Wang J, Tang W, Tu Y, Xu L, Wu F, Tan Z, Sun H, Tian Y, Wong J, Lai PB, Chan SL, Chan AW, Tan PB, Chen Z, Sung JJ, Yip KY, To KF, Cheng AS. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine. 2021 Apr 7;13(588):eaaz6804. doi: 10.1126/scitranslmed.aaz6804. PMID: 33827976.

Wong YC, Liu W, Yim LY, Li X, Wang H, Yue M, Niu M, Cheng L, Ling L, Du Y, Chen SMY, Cheung KW, Wang H, Tang X, Tang J, Zhang H, Song Y, Chakrabarti LA, Chen Z*. Sustained viremia suppression by SHIVSF162P3CN-recalled effector-memory CD8+ T cells after PD1-based vaccination. PLoS Pathogens. 2021 Jun 14;17(6):e1009647.

Yeung ML, Teng JLL, Jia L, Zhang C, Huang C, Cai JP, Zhou R, Chan KH, Zhao H, Zhu L, Siu KL, Fung SY, Yung S, Chan TM, To KK, Chan JF, Cai Z, Lau SKP, Chen Z, Jin DY, Woo PCY, Yuen KY. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell. 2021 Apr 15;184(8):2212-2228.e12.

Gong L, Kwong DL, Dai W, Wu P, Li S, Yan Q, Zhang Y, Zhang B, Fang X, Liu L, Luo M, Liu B, Chow LK, Chen Q, Huang J, Lee VH, Lam KO, Lo AW, Chen Z, Wang Y, Lee AW, Guan XY. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. Nature Communications. 2021 Mar 9;12(1):1540.

Wong YC, Lau SY, Wang To KK, Mok BWY, Li X, Wang P, Deng S, Woo KF, Du Z, Li C, Zhou J, Chan JFW, Yuen KY, Chen H, Chen Z*. Natural Transmission of Bat-like Severe Acute Respiratory Syndrome Coronavirus 2 Without Proline-Arginine-Arginine-Alanine Variants in Coronavirus Disease 2019 Patients. Clinical Infectious Diseases. 2021 Jul 15;73(2):e437-e444.

Zhang Q, Ju B, Ge J, Chan JF, Cheng L, Wang R, Huang W, Fang M, Chen P, Zhou B, Song S, Shan S, Yan B, Zhang S, Ge X, Yu J, Zhao J, Wang H, Liu L, Lv Q, Fu L, Shi X, Yuen KY, Liu L, Wang Y, Chen Z*, Zhang L*, Wang X*, Zhang Z*. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nature Communications. 2021 Jul 9;12(1):4210. doi: 10.1038/s41467-021-24514-w. PMID: 34244522; PMCID: PMC8270942.

Niu M, Wong YC, Wang H, Li X, Chan CY, Zhang Q, Ling L, Cheng L, Wang R, Du Y, Yim LY, Jin X, Zhang H, Zhang L, Chen Z*. Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression. Cell Reports. 2021 Aug 24;36(8):109611.

Zhou D, Zhou R, Chen Z*. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Immunotherapy Advances, Volume 2, Issue 1, 2022, ltab027,

Chu H, Hu B, Huang X, Chai Y, Zhou D, Wang Y, Shuai H, Yang D, Hou Y, Zhang X, Yuen TT, Cai JP, Zhang AJ, Zhou J, Yuan S, To KK, Chan IH, Sit KY, Foo DC, Wong IY, Ng AT, Cheung TT, Law SY, Au WK, Brindley MA, Chen Z, Kok KH, Chan JF, Yuen KY. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. Nature Communications. 2021 Jan 8;12(1):134.

Pang L, Ng KT, Liu J, Yeung WO, Zhu J, Chiu TS, Liu H, Chen Z, Lo CM, Man K. Plasmacytoid dendritic cells recruited by HIF-1α/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma. Cancer Research. 2021 Dec 1;522:80-92.

Zhang BZ, Wang X, Yuan S, Li W, Dou Y, Poon VK, Chan CC, Cai JP, Chik KK, Tang K, Chan CC, Hu YF, Hu JC, Badea SR, Gong HR, Lin X, Chu H, Li X, To KK, Liu L, Chen Z, Hung IF, Yuen KY, Chan JF, Huang JD. A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerg Microbes Infect. 2021 Dec;10(1):874-884. doi: 10.1080/22221751.2021.1921621. PMID: 33890550

Mo Y, To KK, Zhou R, Liu L, Cao T, Huang H, Du Z, Lim CYH, Yim LY, Luk TY, Chan JM, Chik TS, Lau DP, Tsang OT, Tam AR, Hung IF, Yuen KY, Chen Z*. Mitochondrial Dysfunction Associates With Acute T Lymphocytopenia and Impaired Functionality in COVID-19 Patients. Frontiers in Immunology. 2022 Jan 14;12:799896. doi: 10.3389/fimmu.2021.799896.

Zhou R, Wang P, Wong YC, Xu H, Lau SY, Liu L, Mok BW, Peng Q, Liu N, Woo KF, Deng S, Tam RC, Huang H, Zhang AJ, Zhou D, Zhou B, Chan CY, Du Z, Yang D, Au KK, Yuen KY, Chen H, Chen Z*. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine. 2022 Jan;75:103762.

Zhou R, To KK, Peng Q, Chan MC, Huang H, Yang D, Lam HS, Chuang WM, Cai J, Liu N, Au KK, Tsang TY, Yuen KY, Chen Z*. Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses. Clinical and Translational Medicine. 2022 Jan 26;12;1;e720. Doi: 10.1002/ctm2.720

Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, Huang H, Yang D, Au KK, Wang H, Man K, Yuen KY, Chen Z*. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022 Mar 3;77:103904. doi: 10.1016/j.ebiom.2022.103904.

Chen SMY, Wong YC, Yim LY, Zhang H, Wang H, Lui GCY, Li X, Tang X, Cheng L, Du Y, Peng Q, Wang J, Kwok HY, Huang H, Lau TT, Chan DPC, Wong BCK, Liu L, Chakrabarti LA, Lee SS, Chen Z*. Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine. Journal of Virology. 2022 Mar 17:e0216121. doi: 10.1128/jvi.02161-21. Epub ahead of print. PMID: 35297660.

Lian Q, Zhang K, Zhang Z, Duan F, Guo L, Luo W, Mok BW, Thakur A, Ke X, Motallebnejad P, Nicolaescu V, Chen J, Ma CY, Zhou X, Han S, Han T, Zhang W, Tan AY, Zhang T, Wang X, Xu D, Xiang J, Xu A, Liao C, Huang FP, Chen YW, Na J, Randall G, Tse HF, Chen Z, Chen Y, Chen HJ. Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model. Nature Communications. 2022 Apr 19;13(1):2028.

Liu L, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L, Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine. 2022 May 25;14(646):eabn6859.

Ye ZW, Ong CP, Tang K, Fan Y, Luo C, Zhou R, Luo P, Cheng Y, Gray VS, Wang P, Chu H, Chan JF, To KK, Chen H, Chen Z, Yuen KY, Ling GS, Yuan S, Jin DY. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. Cellular & Molecular Immunology. 2022 May;19(5):588-601.

Chiu MC, Li C, Liu X, Yu Y, Huang J, Wan Z, Xiao D, Chu H, Cai JP, Zhou B, Sit KY, Au WK, Wong KK, Li G, Chan JF, To KK, Chen Z, Jiang S, Clevers H, Yuen KY, Zhou J. A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant. Cell Discovery. 2022 Jun 17;8(1):57.

Wang X, Chen X, Tan J, Yue S, Zhou R, Xu Y, Lin Y, Yang Y, Zhou Y, Deng K, Chen Z*, Ye L, Zhu Y. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope. Cell Host Microbe. 2022 Jun 8;30(6):887-895.e4.

Zhou B, Zhou R, Tang B, Chan JF, Luo M, Peng Q, Yuan S, Liu H, Mok BW, Chen B, Wang P, Poon VK, Chu H, Chan CC, Tsang JO, Chan CC, Au KK, Man HO, Lu L, To KK, Chen H, Yuen KY, Dang S, Chen Z*. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Nature Communications. 2022 Jun 23;13(1):3589. doi: 10.1038/s41467-022-31259-7. PMID: 35739114; PMCID: PMC9223271.

Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L, Ho DD. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature. 2022 Jul 5. doi: 10.1038/s41586-022-05053-w. Epub ahead of print. PMID: 35790190.

Peng Q, Zhou R, Liu N, Wang H, Xu H, Zhao M, Yang D, Au KK, Huang HD, Liu L and Chen Z*. Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. Cellular & Molecular Immunology. 2022 Nov;19(11):1302-1310. doi: 10.1038/s41423-022-00924-8. Epub 2022 Oct 12.

Cao T, Liu L, To KK, Lim CY, Zhou R, Ming Y, Kwan KY, Yu S, Chan CY, Zhou B, Huang H, Mo Y, Du Z, Gong R, Yat LT, Hung IF, Tam AR, To WK, Leung WS, Chik TS, Tsang OT, Lin X, Song YQ, Yuen KY, Chen Z*. Mitochondrial regulation of acute extrafollicular B-cell responses to COVID-19 severity. Clinical and Translational Medicine. 2022 Sep;12(9):e1025.

Pang L, Yeung OWH, Ng KTP, Liu H, Zhu J, Liu J, Yang X, Ding T, Qiu W, Wang Y, Chiu TLS, Chen Z, Lo CM, Man K. Postoperative Plasmacytoid Dendritic Cells Secrete IFNα to Promote Recruitment of Myeloid-Derived Suppressor Cells and Drive Hepatocellular Carcinoma Recurrence. Cancer Research. 2022 Nov 15;82(22):4206-4218.

Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, Wang Y, Chan AW, Yan CW, Kwan KY, Wong YC, Li X, Zhou J, To KF, Zhu J, Lo CM, Cheng AS, Chan SL, Liu L, Song YQ, Man K, Chen Z*. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut. 2022 Nov 30:gutjnl-2022-327133.

Zhao F, Fung TY, Chen Z*, Wang H*, Cheung AKL*. Association of human cytomegalovirus in urine with end-organ diseases in stage 2/3 HIV-1-infected individuals. Journal of Clinical Virology. 2023 Jan;158:105351.

Zhou R, Liu N, Li X, Peng Q, Yiu CK, Huang H, Yang D, Du Z, Kwok HY, Au KK, Cai JP, Fan-Ngai Hung I, Kai-Wang To K, Xu X, Yuen KY, Chen Z*. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. The Lancet Regional Health – Western Pacific. 2023 Mar;32:100660.

Luo M, Zhou B, Reddem ER, Tang B, Chen B, Zhou R, Liu H, Liu L, Katsamba PS, Au KK, Man HO, To KK, Yuen KY, Shapiro L, Dang S, Ho DD, Chen Z*. Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. Emerging Microbes & Infections. 2023 Dec;12(1):2146538.